SCHEMBL3338593

SCHEMBL3338593

CC(C)Oc1nc(N)nc2ccc(-c3ccco3)cc12

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.49
HRH1 P35367 2/20 0.47
HRH4 Q9H3N8 2/20 0.47
HRH3 Q9Y5N1 2/20 0.47
KCNH2 Q12809 1/20 0.44
CCNE2 O96020 1/20 0.42
CCNE1 P24864 1/20 0.42
CDK2 P24941 1/20 0.42
ADORA1 P30542 1/20 0.40
PIK3R1 P27986 1/20 0.39
PIK3CA P42336 1/20 0.39
ATM Q13315 2/20 0.38
MAPT P10636 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
AAK1 Q2M2I8 1/20 0.37
DHFR P00374 1/20 0.37
ALK Q9UM73 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3336846 0.83 ADORA2A (0.49) ADORA2AHRH1HRH4HRH3KCNH2
SCHEMBL3336876 0.80 ADORA2A (0.46) ADORA2AHRH1HRH4HRH3KCNH2
SCHEMBL3331728 0.80 ALOX5 (0.41) CDK2ATMMAPT
SCHEMBL3333937 0.79 DHFR (0.48) CCNE2CCNE1CDK2PIK3CAATM
SCHEMBL3337055 0.79 HRH1 (0.46) ADORA2AHRH1HRH4HRH3CDK2
SCHEMBL3333131 0.78 HSP90AB1 (0.47) ADORA2AHRH4CDK2PIK3CAATM
SCHEMBL3332604 0.77 AAK1 (0.44) PIK3CAATMAAK1DHFR
SCHEMBL3336166 0.77 ATM (0.39) CCNE2CCNE1CDK2PIK3CAATM
SCHEMBL3338126 0.77 MAP4K4 (0.43) ADORA2ACDK2PIK3CAATMMAPT
SCHEMBL3337214 0.77 ATM (0.53) CCNE2CCNE1CDK2PIK3CAATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US claimed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US claimed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO claimed
US-8673929-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-03-18 US disclosed
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2010-06-10 US disclosed
WO-2008009077-A2 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100143299-A1 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS OPRD1, IFNAR1, NR4A1 ADORA2A 1968/4885HRH1 124/4885HRH4 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.